Nitric oxide (NO) has been implicated in the development of heart failure, although the source, significance, and functional role of the different NO synthase (NOS) isoforms in this pathology are controversial. The presence of a neuronal-type NOS isoform (NOS1) in the cardiac sarcoplasmic reticulum has been recently discovered, leading to the hypothesis that NOS1-derived NO may notably alter myocardial inotropy. However, the regulation and role(s) of NOS1 in cardiac diseases remain to be determined. Using an experimental model of myocardial infarction (MI) in senescent rats, we demonstrated a significant increase in cardiac NOS1 expression and activity in MI, coupled with the translocation of this enzyme to the sarcolemma through interactions with caveolin-3. The enhanced NOS1 activity counteracts the decrease in cardiac NOS3 expression and activity observed in heart failure. We demonstrated an increased interaction between NOS1 and its regulatory protein HSP90 in post-MI hearts, a potential mechanism for the higher NOS1 activity in this setting. Finally, preferential in vivo inhibition of NOS1 activity enhanced basal post-MI left ventricular dysfunction in senescent rats. These results provide the first evidence that increased NOS1-derived NO production may play a significant role in the autocrine regulation of myocardial contractility after MI in aging rats.
reducing O 2 consumption (5) . Moreover, in the normal human heart and in allograft recipients, intracoronary infusion of NO donors or substance P, which releases NO from the coronary endothelium and enhances cGMP production, improved LV diastolic function by hastening LV relaxation and increasing LV diastolic distensibility (6, 7) . Shah et al. achieved similar lusitropic effects with cGMP analogs, which further supports an intermediary role of this nucleotide in mediating myocardial relaxation (8, 9) .
However, despite much investigation, the critical role of endogenous NO production in the pathophysiology of HF remains controversial. Reduced coronary endothelial vasodilator function is well established in HF, which suggests impairment of the vascular endothelial isoform of NO synthase (NOS3)/endothelium-mediated signaling. Nevertheless, the consequences of NOS overexpression in the myocardium are still controversial. Several studies have demonstrated a physiologically important role for myocardial NO, derived either from NOS2 or NOS3, which accounts for the deteriorating cardiomyocyte contractile status in experimental models of HF, in patients with LV dysfunction, and in human allograft at baseline or after β-adrenergic stimulation (10) . Conversely, recent data have demonstrated an unaltered response to β-adrenergic stimulation in papillary muscles from mice with selective disruption of the gene encoding NOS3. Likewise, others have failed to detect any role for NOS2 induction in HF-associated cardiac dysfunction (11) (12) (13) .
These seemingly conflicting findings may, in part, be due to differences in experimental preparations, but also may be a consequence of the subcellular localization of different NOS isoforms, which have recently been discovered. Indeed, in addition to the well-established paracrine effects of endothelial/endocardial NOS3-derived NO on ventricular function, emerging evidence indicates that a neuronal-type NOS1 isoform in the cardiac sarcoplasmic reticulum (SR) may be involved in the regulation of calcium fluxes and, thus, myocardial inotropy (14) . Indeed, Ashley et al. (15) have recently demonstrated that NOS1 disruption enhances basal contraction and the inotropic response to β-adrenergic stimulation in murine ventricular myocytes, indicating that cardiac NOS1-derived NO plays a significant role in the autocrine regulation of myocardial contractility. However, the expression and activity of NOS1 in pathological conditions, such as HF, have not to date been examined.
Although myocardial infarction (MI) is one of the major etiologies of cardiac failure in the aging population, no study has specifically examined the spatial expression and specific activities of the NOS isoforms in this setting. In the present study, we hypothesized that the apparent paradox of increased myocardial contractility after NOS inhibition in post-MI dysfunction, despite the observed decrease in NOS3-derived NO, could be explained by an increase in NOS1-derived NO in the myocardium. Hence, the aims of the present study were to investigate a) whether cardiac NOS1 expression is enhanced in an experimental model of MI in aging rats; b) whether its activity is increased; and c) whether this is associated with cardiac contractile dysfunction.
MATERIALS AND METHODS

Animals
This study was conducted in accordance with the Guide for the Care and Use of Laboratory Animals, published by the U.S. National Institute of Health (NIH Publication No. 85-23, revised 1996) . A group of 24-month-old senescent male Wistar rats (Charles River, Lyon, France) were subjected to ligation of the left anterior descending coronary artery to cause myocardial infarction as described previously (16) . Sham operation was also performed in age-matched animals. Post-surgery mortality was 40% and late mortality was 10%. Rats were given food and water ad libitum. All experiments were performed 3 months after surgery.
Experimental protocol and hemodynamic study
After anesthesia (ketamine 50-100 mg/Kg; xylazine 50-100 mg/kg, IP), hemodynamic parameters of sham senescent rats (S-Sh) and senescent rats with MI (S-MI) were measured by using a 1.8F high-fidelity pressure transducer (Millar Instruments, Houston, TX) connected to a data acquisition unit (MP100, Biopac Systems Inc., CEROM, Paris, France; 17). The 1.8-Fr Micro-tip Catheter Transducer was inserted into the right common carotid artery and advanced into the LV of the heart for continuous LV pressure measurement. After the placement of the catheter into the LV of the heart, each animal was allowed to stabilize for at least 10 min or until stable blood pressure, heart rate, and LV dP/dt max were observed. Baseline values were then recorded. Digitized data were analyzed to determine aortic systolic and diastolic pressures, LV systolic pressure, LV end diastolic pressure (LEVDP), the rate of rise of LV pressure (+dP/dt max ), and the time constant of isovolumic relaxation (τ; 18).
At the end of the protocol, hearts were weighed and the LV apex and bases were frozen in liquid nitrogen-precooled isopentane for future immunofluorescence and biochemical analysis.
Hemodynamic measurement in vivo: response to NOS1 inhibition
In a subset of both S-Sh and S-MI groups, following the measurements of baseline parameters described above, an intra-abdominal aortic bolus dose of the preferential NOS1 inhibitor SMTC (0.5 mg/kg) was injected and cardiac pressures were continuously measured. Previous experiments from our lab have demonstrated that this concentration of SMTC had no effect on both systolic blood pressure and heart rate.
We calculated τ by the derivative method by the following: LV dP/dt was plotted against the LV pressure (LVP), and the slope (A) of the portion of the plot corresponding to isovolumetric relaxation (between dP/dt min and P min + 5 mmHg) was used to determine the time constant τ, where -1/A equals τ.
Measurement of NOS activity and nitrite concentration in ventricular homogenates
Global NOS activity was measured by the conversion of ( 3 H) L-arginine (NEN/DuPont, Le Blanc Mesnil, France) to ( 3 H)L-citrulline, as in (19) . Rat hearts were homogenized according to (18) . Initial experiments showed that the reaction was linear for 20 min and that it was inhibited in a concentration-dependent manner by addition of the nonselective NOS inhibitor (L-NAME, Sigma, Saint Quentin Fallavier, France) to the reaction buffer. To analyze the activity of the specific NOS isoforms, assays were performed in presence of either ethylene diamine tetraacetate (EDTA; 1 mmol/L) to inhibit the constitutively expressed isoforms of NOS (NOS1 and NOS3); SMTC, the preferential inhibitor of NOS1; or L-NAME. Each inhibitor was used at concentrations ranging from 10 −15 to 10 −3 mol/L. Activities of the different isoforms were expressed as percent of the basal total NOS activity (20) . Nitrite concentration was quantified in 20 µL heart extract and was calculated using a standard curve of nitrite as in (21) .
Western blotting experiments
Samples of LV (40 mg , Amersham) and quantified by densitometry using a computer-based imaging system (Fujifilm Las-1000, Raytest, Paris, France) and normalized to protein amount present on the gel.
Immunoprecipitation and immunoblotting
Co-immunoprecipitation analysis was performed to study the interaction between both caveolin-3 (Cav-3) and HSP90 with NOS1 in whole LV extracts. Briefly, LV lysates (300 µg protein) were incubated overnight at 4°C with either a mAb for caveolin-3 or a pAb for NOS1 (SC-1025, Santa Cruz) at a final concentration of 5 µg/mL in 400 µL of IP buffer [1% Triton X-100, and in mmol/L: 150 NaCl; 10 Tris-HCl, pH 7.4; 1 EDTA, 1 ethyleneglycol-bis(β-aminoethyl ether)-N,N,N′,N′-tetraacetic acid (EGTA), 0.2 orthovanadate, 0.2 PMSF]. Immune complexes were precipitated for another 3 h by the addition of anti-mouse IgGconjugated agarose (50 µL) or protein A-conjugated agarose (15 µL), centrifugated, washed three times, and then boiled in Laemmli loading buffer. Samples were loaded and separated by SDS-PAGE and immunoblotted with a mAb for NOS1 (1:1000) or a mAb for HSP90 (1:2500), respectively.
Immunolabeling
Cryostat sections of heart tissue (7 µm thick), postfixed in acetone/methanol (1:1) at -20°C, were preincubated in phosphate-buffered saline (PBS) containing 5% bovine serum albumin (BSA) for 30 min at 21°C. Mouse mAbs for NOS2 and NOS3 (1:100, Transduction Laboratories) and rabbit pAb for NOS1 (1:50, Santa Cruz) were applied for 1 h at 21°C. After washing, sections were incubated with mouse mAb for vinculin (1:50, Sigma) or rabbit pAb for either von Willebrand factor (1:50, Sigma) or caveolin-1α (1:100, Santa Cruz) for 1 h at 21°C. Following incubations with fluorescein-conjugated sheep anti-mouse IgG (1:40) and Texas-Red-conjugated donkey anti-rabbit IgG (1:40) (Amersham), mounted sections were observed by using a Leica epifluorescence microscope.
Morphometry, including automatic image analysis (Optilab, Graftek, Mirmande, France) was applied to evaluate myocyte diameter in LV posterior walls after fibronectin-immunolabeling.
Statistical analysis
Data are expressed as mean ± SEM. Comparisons between groups were made by Student's unpaired t-test. P<0.05 was considered significant.
RESULTS
Hemodynamic parameters
Morphological and physiological data are shown in Table 1 . In the S-MI group, the heart weight-to-body weight ratio was higher than that in S-Sh rats (P<0.05). Diastolic parameters were significantly altered in S-MI hearts compared with S-Sh hearts, as demonstrated by an increase in the LVEDP (P<0.05). However, the time course of pressure decline (τ) as well as LV dP/dt max were similar in the two groups, as described previously (22) .
NOS expression and activity in post-MI rat hearts
In the S-MI group, both the nitrite concentration and calcium-dependent NOS activity were similar to that of S-Sh rats (Fig. 1A) . A background calcium-independent NOS activity was also detected in S-Sh hearts, which was similar in S-MI rat myocardium. However, no NOS2 activity was measured in presence of EDTA (0.1 mmol/L, data not shown), and NOS2 was undetectable in protein extracts from the same hearts by immunoblotting (compared with the strong positive control, Fig. 1B) , and in tissue sections from the two animal groups by immunostaining (not shown). Although total calcium-dependent activity was unchanged in S-MI rats, this was associated with a dramatic decrease in NOS3 protein expression in LV extracts from these animals compared with S-Sh rats ( Fig. 2A; P<0 .001 vs. S-Sh, n=14/group). Using immunofluorescence, we found that NOS3 was detectable in all endothelial cells as described previously ( Fig. 2B; 23 ). NOS3 distribution did not vary between the S-Sh and S-MI rat hearts, but the intensity of the NOS3 staining slightly decreased in S-MI tissue, as demonstrated by the co-staining with two different endothelial cell markers, that is, caveolin-1α and von Willebrand factor (Fig. 2B c and g ). Notably, the NOS3 fluorescent signal within cardiomyocyte did not differ from the background level observed in the absence of the primary antibody in both groups (Fig. 2B d and h) .
The above observations led us to hypothesize that the apparent discrepancy between the maintenance of either nitrite concentration or calcium-dependent NOS activity in S-MI hearts, despite the decrease in NOS3 expression, may be due to an increase in NOS1 expression. Fig.  3A confirmed the presence of NOS1 in S-MI myocardium as well as demonstrated a twofold increase in NOS1 expression in these hearts compared with the S-Sh group (P<0.001). The level of NOS1 was linearly correlated with myocyte diameter (n=11, r 2 =0.792, P=0.0002) and LVEDP (n=24, r 2 =0.299, P=0.0057), indicating that NOS1 expression could be related to the degree of ventricular hypertrophy and to the degree of heart failure. The respective up-and down-regulation of NOS1 and NOS3 in the two animal groups suggests that the two constitutive NOS isoforms may have a reciprocal regulation. This hypothesis was verified by the correlation between NOS1/NOS3, which reveals that the level of NOS1 is negatively and linearly correlated with that of NOS3 (n=23, r=-0.561, P=0.0035; Fig. 3B ).
We used both preferential and nonspecific NOS inhibitors to determine NOS1 activity (Fig.  4) . The preferential NOS1 inhibitor SMTC (10 −11 mol/L) inhibited NOS activity by >80% in S-MI hearts but only by 40% in the S-Sh group. The same results were obtained with a second NOS1 inhibitor, 7-nitroindazole (same dose range, data not shown). However, dose-response curves indicated that L-NAME, a nonselective NOS inhibitor, depressed NOS activities by a similar extent in both groups. Consequently, in the S-MI group, the left-shift in the doseresponse curve in the presence to SMTC supports the concept of an enhanced expression and/or activity of NOS1 post-MI in senescent rat heart.
Taken together these results demonstrate that 1) NOS1 expression is up-regulated; 2) the enzyme is functional; and 3) its activity is increased late after MI in senescent rats. In addition, the present data indicate that both NOS3 expression and specific activity are decreased post-MI, as described previously (24) .
Changes in HSP90 abundance in rat hearts
NOS1 activity has previously been shown to be regulated post-translationally via its stimulatory interaction with the chaperone protein HSP90 in cultured cells (25, 26) . Therefore we assessed potential changes in the abundance of HSP90 by Western blot analysis. Fig. 5A shows a significant increase in HSP90 protein expression in LV extracts from S-MI compared with S-Sh hearts (P<0.005 vs. S-Sh, n=6 per group). Physical interactions between NOS1 and HSP90 were subsequently investigated by using the co-immunoprecipitation approach. As seen in Fig. 5B , HSP90 can form a complex with NOS1 in Triton X-100 lysates of S-Sh and S-MI hearts. We also demonstrated that this level of interaction is markedly increased in the S-MI group (10-fold increase, P<0.0001, n=5 per group).
NOS 1 distribution within myocardium
Immunofluorescence revealed a linear intracellular pattern of NOS1 expression in S-Sh cardiomyocytes, which was longitudinal and transverse, consistent with previous data for antigens localized to the longitudinal and junctional sarcoplasmic reticulum (Fig. 6A a-c) . Interestingly, a unique NOS1 localization was apparent at the levels of both sarcolemma and T tubules of S-MI cardiomyocytes, as corroborated in sections co-stained for NOS1 and vinculin as a sarcolemmal marker (Fig. 6A d-f) . These results suggest a translocation of NOS1 from the sarcoplasmic reticulum to the sarcolemma after MI. No fluorescent signal was observed in the absence of anti-NOS1 antibody (not shown).
MI induced NOS1 translocation to the sarcolemma
We further assessed whether NOS1 is translocated to the sarcolemma and whether it interacts in situ with its well-described scaffolding protein Cav-3 [as described previously in skeletal muscle (27) ], by using co-immunoprecipitation to measure physical interactions between Cav-3 and NOS1. Fig. 6B displays that Cav-3 from OG lysates of S-Sh and S-MI hearts coprecipitates with NOS1, and the amounts of NOS1/Cav-3 complexes are dramatically increased in the S-MI group (40-fold increase, P<0.0001, n=5 per group). The reverse experiment, that is, co-immunoprecipitation of NOS1 with Cav-3 by Western blotting, confirmed these findings. Taken together these data demonstrate that a significant level of NOS1 is translocated to the sarcolemma, where it interacts with Cav-3 after MI.
Effect of NOS1 inhibition on LV contractile function
The time constant of ventricular relaxation (τ) was determined in vivo by the derivative method (Fig. 7A) . The baseline values for τ were 14.1 ± 2.9 and 16.7 ± 3.2 ms in the S-Sh and S-MI groups, respectively. Inhibition of NOS1 by SMTC significantly increased τ in the S-MI group (P<0.001, n=3) but caused no change in the S-Sh group (P=0.29, n=3). Similarly, NOS1 inhibition significantly increased peak LV dP/dt max in the S-MI group (P<0.05, n=3), but had no effect in the S-Sh group (P=0.3, n=3; Fig. 7B ).
DISCUSSION
Using biochemical, immunological, and in vivo physiological approaches, the principal new findings of this study are the following: 1) NOS1 expression is increased in post-MI senescent rats and is predominantly expressed at the level of the sarcolemma via its interaction with caveolin-3; 2) total NOS activity, similar in hearts from senescent rats with or without MI, is dramatically inhibited by a preferential NOS1 inhibitor after MI in aging rats; and 3) in vivo inhibition of NOS1 increases post-MI LV dysfunction in senescent rats.
Changes in NOS expression
Although NOS1 and NOS3 are known to be expressed within the heart, the subcellular distribution and expression of these two constitutive isoforms are still unclear. The cellular distribution and physiological roles of NOS1 have been the subject of relatively few reports in the normal heart and none in the failing heart, to date. Recent studies, however, have indicated that cardiac myocytes, in addition to neurons and vascular smooth muscle cells, express NOS1 (14) . The present study demonstrates a cell-specific distribution of NOS1 and NOS3 in the myocardium. Immunofluorescence experiments in the present study confirmed and extended previous observations indicating that NOS1 1) is expressed in the cardiac myocytes of both adult and senescent rat hearts, and 2) exhibits a major redistribution toward the sarcolemma and T-Tubules after MI. Moreover, Western blot and calcium-dependent NOS activity experiments not only strengthen the fact that NOS1 is expressed in senescent rat hearts but also demonstrate that both its expression and its specific activity are increased after MI. On the other hand, NOS3 immunostaining was detected only in the endothelium of myocardial coronary vessels. Virtually no specific NOS3 staining was detected within cardiac myocytes, whatever the group. Although this result agrees with many previous reports, it differs from others showing that cardiac myocytes indeed express NOS3 (24, 28) . In addition, according to data obtained in dogs (29) and humans (30, 31), our findings indicate that NOS3 expression and activity decrease after MI in senescent hearts. These results are in accordance with the occurrence of endothelial dysfunction during HF. Finally, under our experimental conditions, late after MI, NOS2 is undetectable in surviving myocardium as well as in the infarction scar. This result appears to contrast with either human (32) or rabbit data (33, 34) . However, NOS2 expression was found early after injury, although only in inflammatory cells. The absence of NOS2 in the present study is likely to be due to the few inflammatory cells present at this late-stage post-ischemia compared with the young adult (35) . Consequently our data provide the first biochemical and functional evidence that NOS1 participates in maintaining myocardial NO production post-MI.
Post-MI NOS activity
One important finding of the study is that the up-regulation of NOS1 appears to compensate for the down-regulation of NOS3 expression and activity, as revealed by the similar nitrite concentrations and total Ca 2+ -dependent NOS activity in S-Sh and S-MI groups. Such a constant NOS activity was also recently observed in the human failing heart (36). To our knowledge, this is the first demonstration of a reciprocal expression of the constitutive NOS isoforms (NOS1 and NOS3) in the post-MI myocardium. These data, therefore, extend those obtained in normal ferret ventricle, suggesting that NOS1 expression was approximately inverse to that of NOS3 (37) . In skeletal muscle where NOS1 normally predominates (38, 39) , sepsis is associated with a reciprocal expression of the two constitutive NOS isoforms that lead to up-regulation of NOS3 (40) . Accordingly, it emerges that reciprocal expression of the constitutive NOS isoforms in diseased muscle might represent a ubiquitous compensatory mechanism to maintain certain levels of NO, independent of the NOS isoform primarily affected.
Molecular partners of NOS1
In addition to changes in NOS1 abundance, the production of NO in situ can be modulated through post-translational regulation of NOS1. Previous studies have demonstrated that NOS1 activity is influenced by its reciprocal interaction with Cav-3, the structural protein of plasmalemmal caveolae in skeletal muscle and cardiomyocytes (41) (42) (43) . To further demonstrate the specific subcellular change in the localization of NOS1 after MI in the senescent myocardium, we assessed the protein interaction between NOS1 and Cav-3. Our results clearly demonstrate that MI induced a precise spatial confinement of NOS1 in the cardiomyocyte sarcolemma, where the enzyme interacts with the myocyte caveolae scaffolding protein, Cav-3. This increased amount of NOS1 associated to Cav-3 could constitute an increased pool of enzyme that can be activated upon stimulation. Of note, these changes in Cav-3/NOS1 complexes abundance cannot be correlated directly with calciumdependent NOS activity, as measured by in vitro assays, because measurements of enzymatic activity were performed in a buffer containing excess calcium and calmodulin sufficient to dissociate the NOS1/Cav-3 heteroduplexes. Consequently, our results mostly reflect the maximal activity proportional to NOS1 abundance.
Our data also show for the first time that HSP90 is a physiological binding partner of NOS1 in cardiomyocytes and that their interaction significantly increases in the post-MI heart. Therefore, taken together, the chronic effects of age-associated post-MI LV dysfunction on the interaction between Cav-3/NOS1, as well as the regulation of NOS1 by HSP90, may account, in part, for the results obtained with NOS1 inhibition observed for both the in vitro activity and the in vivo modulation of basal myocardial function (as discussed below).
NOS1 regulation of basal myocardial contractility in the post-MI rat heart
The role of NO in modulating cardiac function has been studied by using several approaches, including administration of NOS inhibitors, administration of NO donors, and use of genetically altered animals. It has also been studied in several models, including cardiac ventricular myocytes, papillary muscle preparations, isolated perfused hearts, and intact animals. Although it has been suggested that excessive NO production contributes acutely to contractile depression in HF, direct evidence to support this is weak. On the one hand, it has been suggested that induction of high-output NOS2 in failing myocardium leads to excess NO production. This view has received support from studies reporting the appearance of circulating cytokines capable of stimulating NOS2 induction in HF (44, 45) . On the other hand, however, induction of NOS2 is not observed in different models of HF (24), including ours. Similarly, studies in the NOS3 −/− mice produced conflicting results. Gyurko et al. (18) found an enhanced LV dP/dt max in response to β-adrenergic stimulation in these mice, whereas Vandecasteele et al. (11) found no change in either calcium current or papillary muscle contractility in the same murine model. These conflicting findings may be explained by the discovery of a NOS1 gene product on the cardiac SR. It has been suggested that NOS1-derived NO may inhibit SR Ca 2+ -ATPase (SERCA2a) function (14) , leading us to investigate whether NOS1-derived NO could acutely influence post-MI LV contractile dysfunction in the aging heart. Using an in vivo approach, we demonstrated that myocardial contractility is indeed significantly increased when NOS1 activity is blocked by SMTC in senescent MI rats. These results support and extend those of Ashley et al. (15) , obtained from isolated cardiomyocytes subjected to NOS1 inhibition or from NOS1 −/− mice. Our results also indicate that basal NOS1-derived NO production is important in the regulation of ventricular relaxation in the failing heart, because τ is significantly increased in senescent MI rat hearts after the administration of SMTC. Therefore, these results bring new insight to previous data obtained by using nonselective NO blockers in humans (6) or in isolated guinea pig hearts (46) .
Multiple changes in downstream signaling pathways may be involved in the effects of NOS1-derived NO on cardiac contractility and relaxation. For example, NO can directly regulate the ryanodine-sensitive calcium channel of the SR (47) (48) (49) and may also decrease contractility by reducing myocardial phosphocreatine and ATP pools (50) . Furthermore, elevated cGMP levels may stimulate cAMP phosphodiesterase, thereby promoting degradation of cAMP. Additionally, cGMP-activated protein kinase G may block activation of sarcolemmal L-type calcium channels, resulting in decreased calcium influx. Indeed, previous work indicates that myocardial NO production can tonically inhibit the L-type calcium current in frog (51) and guinea pig cardiac myocytes (52) . During ventricular relaxation, cGMP-activated protein kinase G phosphorylates phospholamban, thereby disinhibiting the SR Ca 2+ ATPase calcium channel and increasing calcium reuptake into the SR. However, Ashley et al. (15) have recently shown that the calcium current density is increased and that the current inactivation is slower in cardiomyocytes from NOS1 −/− mice or after NOS1 inhibition. Their data thus suggest that the main effect of NOS1 in intact myocytes may not be at the level of SERCA2a but at the L-type calcium channel (53) .
Study limitations
Several potential limitations should be mentioned. First, LV dP/dt max is not a perfect index of myocardial contractility. An in vivo study is also limited in terms of the extent of mechanistic assessment possible. Thus, further in vitro experiments will be required to assess precisely 1) the roles of NOS1/Cav-3 and NOS1/HSP90 interactions in modulating cardiomyocyte contractility and 2) the effects of an increased NOS1-derived NO production on calciumhandling and myofilament sensitivity in HF, a pathology characterized by electromechanical dysfunction and calcium-handling abnormalities. Of note, ex vivo Ca-dependent NOS activity, as measured in our in vitro assays, mostly reflects the V max proportional to the abundance of Ca-sensitive NOS in the cardiac extracts and does not necessarily reflect the true level of in vivo NO production because enzymatic activity measurements are performed in a buffer containing an excess of exogenous calcium, calmodulin, and BH4 sufficient to dissociate the NOS3/Cav-1 and NOS1/Cav-3 complexes. In addition, the changes observed in NOS activity cannot be directly correlated with those in either caveolin isoform expression or increased interactions between NOS1 and HSP90.
Study conclusions and implications for heart failure management
In summary, our data indicate that myocardial NOS1-derived NO production is increased and may inhibit basal myocardial contractility in HF associated with senescence. Moreover, increasing consideration is being given to the notion that local concentrations of NO govern subcellular processes in microdomains, such as caveolae. An up-regulation of Cav-3, the specific isoform present in the cardiomyocyte, in failing myocardium supported the larger increase in LV dP/dt max in response to dobutamine in HF patients compared with normal subjects during intracoronary NOS inhibitor (L-NMMA) infusion (54) . These above findings together with our results, which demonstrate an increased interaction between NOS1 and Cav-3 in the post-MI myocardium, may account, at least in part, for the previously observed effects of NOS inhibition in vivo (54) . However, further experiments will be needed to test this hypothesis.
Finally, from the published observations, it may be concluded that the current experimental and clinical evidence in support of a primary role for NOS2-or NOS3-derived myocardial NO in the deteriorating hemodynamic status of the failing heart, either at baseline or after β-stimulation, is unresolved. However, in light of new findings from our laboratory demonstrating the same regulation of NOS1 in end-stage human HF (T. D., P. R., J.L.S, C. H, manuscript in preparation), such an involvement of NOS1-derived NO production in myocardial dysfunction during HF, as demonstrated herein, may be of particular physiological relevance. 
